Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Motivational Interviewing for HCV Elimination
This study addresses a difficult barrier to hepatitis C elimination, specifically development and maintenance of a productive relationship between the health care provider and patient to ensure both treatment success and…
- Trial name
- NCT03804814
- Testing
- Motivational Interviewing Training
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Nova Scotia Health Authority
Pruritus, Liver Cirrhosis, Biliary
Treatment of Cholestatic Pruritus With Sertraline
The goal of this study is to find an effective and well-tolerated medical therapy for itching due to liver disease. Persons with primary biliary cirrhosis or chronic hepatitis C are currently being enrolled in the study.
- Conditions
- Pruritus, Liver Cirrhosis, Biliary, Hepatitis C
- Trial name
- NCT00058903
- Testing
- sertraline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, Hepatitis C
Multicenter Performance Study of QuadQuik Invitro Diagnostic Device
To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
- Conditions
- HIV Infections, Hepatitis C, Hepatitis B, Syphilis Infection
- Trial name
- NCT05692505
- Testing
- QuadQuik
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genlantis Diagnostics
HIV Infections, Hepatitis C
Tajik Migrant Health Education Study
This study will test the efficacy of a peer-education prevention intervention to reduce risky drug, alcohol, and sexual behaviors among male Tajik labor migrants who inject drugs (MWID) while working in Moscow.
- Conditions
- HIV Infections, Hepatitis C, Risky Health Behavior, Risk Reduction Behavior
- Trial name
- NCT04853394
- Testing
- MASLIHAT, TANSIHAT
- Where
- Russia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Hepatitis C, Substance Use Disorders
Opportunstic Hepatitis C Virus Treatment
The project will assess the effect of opportunistically treating hepatitis C virus (HCV) infection immediately when HCV-infected people who inject drugs are hospitalized for acute care in psychiatric, interdisciplinary…
- Trial name
- Opportuni-C (NCT04220645)
- Testing
- Opportunstic treatment, Standard of care
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- University Hospital, Akershus
Heart Failure
Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)
This study is being conducted to determine safety and effectiveness of transplanting hearts from Hepatitis C-positive donors into Hepatitis C-negative patients on the heart transplant waitlist, who will then be treated with…
- Trial name
- USHER (NCT03146741)
- Testing
- Zepatier
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Hepatitis C, Liver Diseases
Improving Hepatitis C Treatment in Injection Drug Users
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.
- Conditions
- Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
- Trial name
- NCT00148031
- Testing
- Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- State University of New York - Upstate Medical University
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Chronic Hepatitis B
4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
Open-label studies, anecdotal reports, and in vitro scientific research indicate that 4-methylumbelliferone (active ingredient of the dietary supplement Heparvit®) may prevent and reverse the symptoms and complications of chronic…
- Trial name
- NCT00225537
- Testing
- 4-Methylumbelliferone (Heparvit®)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- MTmedical Institute of Health
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve…
- Trial name
- NCT01483742
- Testing
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys]
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or…
- Trial name
- JKB122 (NCT02293941)
- Testing
- JKB-122 5mg, JKB-122 15mg, JKB-122 35mg
- Where
- 14 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Hepatitis B, Chronic, Adults
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
In South America, the prevalence of HBV is variable but high (> 8%) in the Amazon basin. In some areas, a third of HBsAg carriers are also infected with HDV, a major comorbidity factor.
- Trial name
- NCT04886102
- Testing
- An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital
- Where
- French Guiana
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier de Cayenne
Hepatitis C
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.
- Trial name
- NCT01467505
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 22 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.
- Trial name
- NCT01280656
- Testing
- Conventional Interferon, Peginterferon Alfa-2a, Peginterferon Alfa-2b
- Where
- 37 sites in Brazil
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Renal Cell Carcinoma
Association Between Hepatitis C Infection and Renal Cell Carcinoma
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered…
- Conditions
- Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT01405183
- Testing
- Hepatitis C testing
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Henry Ford Health System
Chronic Hepatitis C Virus Infection
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Although infection with the hepatitis C virus (HCV) can result in acute hepatitis; it more commonly progresses to chronic hepatitis. The acute process is most often asymptomatic. Acute HCV typically leads to chronic infection.
- Trial name
- TPEGHCVS (NCT01813266)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Intermountain Health Care, Inc.
Hepatitis C Virus
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3
The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given…
- Trial name
- NCT00143000
- Testing
- Peginterferon alfa-2a 40KD and Ribavirin
- Where
- Sweden
- Volunteers
- 392 people
- Sponsor
- NORDynamIC Study Group
Hepatitis C
Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy
The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving…
- Trial name
- NCT02877199
- Testing
- Triple therapy
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis C
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
- Trial name
- NCT00749138
- Testing
- tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis C
The Sublimated Mare Milk Supplement in Hepatitis C
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
- Trial name
- NCT03669835
- Testing
- Mare milk supplement, Standard therapy
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.